ILC Therapeutics’
COO Dawn Firmin spoke with Manufacturing Chemist on the challenges in
developing a novel drug class, and the Company’s journey so far and how
it addressed some of these key challenges.
ILC Therapeutics
A cytokine-engineering company pioneering Hybrid Interferons as first-in-class therapeutics
Our platform technology allows us to engineer novel Hybrid Interferons targeted against specific diseases, each with a large unmet medical need and clear commercial market.
Our lead candidate - Alfacyte - is a broad-spectrum antiviral in development as a therapeutic for RSV.
Latest News
ILC Therapeutics completes £2.5m financing and bolsters C-suite
ILC Therapeutics, a specialist developer of hybrid interferons, a new drug class engineered for improved therapeutic profiles across multiple indications, announces that it has successfully completed a fundraise of £2.5m.
ILC completes investment round and appoints Dr Owain Millington as Vice President and Head of Preclinical Development
Scottish biotech ILC Therapeutics has completed its most recent investment round and is on track to commercialise a suite of antiviral medicines for the treatment of respiratory infections including SARS-CoV-2.